Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation

Expert Opinion on Biological Therapy

Volumn 10, Issue 6, 2010, Pages 959-969

  Campara, Maya ^a   Tzvetanov, Ivo G ^a   Oberholzer, Jose ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Daclizumab; IL 2 receptor inhibitor; Induction immunosuppression; Solid organ transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ANAPHYLAXIS; ASPERGILLOSIS; BACTERIAL INFECTION; BASAL CELL CARCINOMA; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HERPES ZOSTER; HOT FLUSH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE GRAFT; INTESTINE GRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; ORGAN TRANSPLANTATION; PNEUMONIA; PROTEIN FUNCTION; PYELONEPHRITIS; REVIEW; SEPTICEMIA; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION IMMUNOLOGY;

EID: 77952161958     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.485187     Document Type: Review

References (49)

1. Robb RJ, Munck A, Smith KA. T cell growth factor receptors quantitation, specificity, and biological relevance. J Exp Med 1981;154(5):1455-1474
2. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;10(24):10029-10033
3. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-tac) reactive with activated and functionally mature human T cells. I. Production of anti-tac monoclonal antibody and distribution of tac (+) cells. J Immunol 1981;126(4):1393-1397
4. Depper JM, Leonard WJ, Robb RJ, et al. Blockade of the interleukin-2 receptor by anti-tac antibody: Inhibition of human lymphocyte activation. J Immunol 1983;131(2):690-696
5. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003;3(1):50-52
6. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab triple therapy study group. N Engl J Med 1998;338(3):161-165
7. Zenapax product monograph. F. Hoffmann-La Roche (Basel), Basel, Switzeland; 1997
8. ter Meulen CG, Baan CC, Hene RJ, et al. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001;72(10):1709-1710
9. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003;75(8):1260-1266
10. Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000;69(9):1867-1872
11. Jain A, Valentini RP, Gruber SA, et al. Two-dose daclizumab induction in pediatric renal transplantation. Pediatr Transplant 2009;13(4):490-494
12. Pham K, Kraft K, Thielke J, et al. Limited-dose daclizumab versus basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005;37(2):899-902
13. Joyal D, Cantarovich M, Cecere R, Giannetti N. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation. Clin Transplant 2004;18(5):493-496
14. Ortiz V, Almenar L, Martinez-Dolz L, et al. Induction therapy with daclizumab in heart transplantation--how many doses? Transplant Proc 2006;38(8):2541-2543
15. Koch M, Niemeyer G, Patel I, et al. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002;73(10):1640-1646 (Pubitemid 34568679)
16. Figueras J, Bernardos A, Prieto M, et al. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant Proc 2002;34(5):1511-1513
17. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002;2(5):454-460
18. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 1999;67(1):110-115
19. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002;73(7):1100-1106
20. Abu-Elmagd K, Fung J, McGhee W, et al. The efficacy of daclizumab for intestinal transplantation: preliminary report. Transplant Proc 2000;32(6):1195-1196
21. Carreno MR, Kato T, Weppler D, et al. Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants. Transplant Proc 2001;33(1-2):1015-1017
22. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Eng J Med 2000;342(9):613-619
23. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352(26):2705-2713
24. Kobashigawa J, David K, Morris J, et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005;37(2):1333-1339
25. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001;20(12):1282-1290
26. Garrity ER Jr, Villanueva J, Bhorade SM, et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001;71(6):773-777
27. Grego K, Arnol M, Bren AF, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Transplant Proc 2007;39(10):3093-3097
28. Nair MP, Nampoory MR, Johny KV, et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001;33(5):2767-2769
29. Lin M, Ming A, Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin transplant 2006;20(3):325-329
30. Abou-Jaoude MM, Ghantous I, Najm R, et al. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant proc 2003;35(7):2731-2732
31. Alloway RR, Hanaway MJ, Trofe J, et al. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc 2005;37(2):802-803
32. Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006;6(10):2384-2390
33. Kim MJ, Tsinalis D, Franz S, et al. ATG-fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant 2008;13(4):21-27
34. Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009;20(6):1385-1392
35. Lischke R, Simonek J, Davidova R, et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc 2007;39(1):205-212
36. Mullen JC, Oreopoulos A, Lien DC, et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007;26(5):504-510
37. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs alemtuzumab (with lower dose maintenance immunosuppression) vs daclizumab in renal transplantation at 24 months of follow-up. Clin transplant 2008;22(2):200-210
38. Garcia M, Weppler D, Mittal N, et al. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant Proc 2004;36(2):323-324
39. Lauro A, Amaduzzi A, Dazzi A, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: a comparison of two different regimens on 29 recipients during the early post-operative period. Dig Liver Dis 2007;39(3):253-256
40. Zanfi C, Lauro A, Cescon M, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Transplant Proc 2010;42(1):35-38
41. Lacha J, Simova M, Noskova L, et al. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients. Transplant Proc 2001;33(3):2273-2274
42. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005;80(4):477-481
43. Campos A, Lage E, Hinojosa R, et al. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (zenapax) in cardiac transplantation at our center. Transplant Proc 2005;37(3):1548-1549
44. Wiland AM, Philosophe B. Daclizumab induction in solid organ transplantation. Expert Opin Biol Ther 2004;4(5):729-740
45. Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Ther 2007;7(10):1583-1596
46. Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84(7):829-835
47. Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13(11):1521-1531
48. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009;9(2):327-336
49. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7(11):2619-2625